Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: In vitro/in vivo evaluation in induced ulcerative colitis

Journal of Drug Targeting

Volumn 19, Issue 2, 2011, Pages 140-153

  Varshosaz, Jaleh ^a   Emami, Jaber ^a   Ahmadi, Fatemeh ^a   Tavakoli, Naser ^a   Minaiyan, Mohsen ^a   Fassihi, Afshin ^a   Mahzouni, Parvin ^a   Dorkoosh, Farid ^b  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Budesonide; Colitis; Colon drug delivery; Dextran; Prodrugs

Indexed keywords

ACETIC ACID; BUDENOFALK; BUDESONIDE; BUDESONIDE 21 HEMIGLUTARATE DEXTRAN; DEXTRAN; GLUTARIC ACID; HYDROCHLORIC ACID; MESALAZINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COLON; CONTROLLED STUDY; DRUG DEGRADATION; DRUG EFFICACY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; EVALUATION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; SMALL INTESTINE; STOMACH; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANHYDRIDES; ANIMALS; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; COLITIS, ULCERATIVE; COLON; DEXTRANS; DISEASE MODELS, ANIMAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLUTARATES; HYDROGEN-ION CONCENTRATION; MALE; MESALAMINE; MOLECULAR WEIGHT; RATS; RATS, WISTAR;

EID: 78650534007     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/10611861003801826     Document Type: Article

References (30)

1. Anderson BD, Taphouse V. (1981). Initial rate studies of hydrolysis and acyl migration in methylprednisolone 21-hemisuccinate and 17-hemisuccinate. J Pharm Sci, 70, 181-186. (Pubitemid 11131225)
2. Aslan AM, Temiz M, Atik E, Polat G, Sahinler N, Besirov E, Aban N, Parsak C. (2007). Effectiveness of mesalamine and propolis in experimental colitis. Adv Ther, 24, 1085-1097. (Pubitemid 350274788)
3. Bickston SJ, Cominelli F. (1998). Inflammatory bowel disease: Short- and long-term treatments. Disease-a-Month, 44, 141-172. (Pubitemid 28046256)
4. Binder V. (2004). Epidemiology of IBD during the twentieth century: An integrated view. Best Prac Res Clin Gastroenterol, 18, 463-479. (Pubitemid 38667460)
5. Braughler JM. (1985). Ester prodrugs of steroids. EP 156643.
6. Canevari M, Castagliuolo I, Brun P, Cardin M, Schiavon M, Pasut G, Veronese FM. (2009). Poly(ethylene glycol)-mesalazine conjugate for colon specific delivery. Int J Pharm, 368, 171-177.
7. Cooper HS, Murthy SNS, Shah RS, Sedergran D. (1993).Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest, 69, 238-249. (Pubitemid 23262505)
8. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Pena AS, Meuwissen SGM, Van Rees EP. (1998). Chronic experimental colitis induced by dextran sulfate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immuno, 114, 385-391. (Pubitemid 28539597)
9. Edsbacker ST, Andersson T, McKeage K, Goa KL. (2004). Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet, 43, 803-821. (Pubitemid 39382221)
10. El-Medany A, Mahgoub A, Mustafa A, Arafa M, Morsi M. (2005). The effects of selective cyclooxygenase-2 inhibitors, celecoxib and rofecoxib, on experimental colitis induced by acetic acid in rats. Eur J Pharmacol, 507, 291-299. (Pubitemid 40126866)
11. Fedorak RN, Bistritz L. (2005). Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Del Rev, 57, 303-316. (Pubitemid 39536104)
12. Friend DR. (1998). Issues in oral administration of locally acting glucocorticosteroids for treatment of inflammatory bowel disease. Aliment Pharmacol Ther, 12, 591-603. (Pubitemid 28329337)
13. Gorgulu S, Yagci G. (2006). Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid induced colitis in rats. Dig Dis Sci, 51, 480-487.
14. Gupta M, Bhargava HN. (2006). Development and validation of a highperformance liquid chromatographic method for the analysis of budesonide. J Pharm Biomed Anal, 40, 423-428. (Pubitemid 43143349)
15. Harboe E, Larsen C, Johansen M, Olesen HP. (1989). Macromolecular prodrugs. XV. Colon-targeted delivery-bioavailability of naproxen from orally administered dextran-naproxen ester prodrugs varying in molecular size in the pig. Pharm Res, 6, 919-923. (Pubitemid 20078440)
16. Klotz U, Schwab M. (2005). Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease. Adv Drug Del Rev, 57, 267-279. (Pubitemid 39536102)
17. Knigge KL. (2002). Inflammatory bowel disease. Clin Cornerstone, 4, 49-57. (Pubitemid 34228952)
18. Lee JS, Jung YJ. (2001). Synthesis and properties of dextran-nalidixic acid ester as a colon-specific prodrug of nalidixic acid. Drug Dev Ind Pharm, 27, 331-336. (Pubitemid 32531599)
19. McKeage K, Goa KL. (2002). Budesonide (Entocort EC capsules): A review of its therapeutic use in the management of active Crohn's disease in adults. Drugs, 62, 2263-2282. (Pubitemid 35256136)
20. McLeod AD, Friend DR. (1993). Synthesis and chemical stability of glucocorticoid-dextran esters: Potential prodrugs for colonspecific delivery. Int J Pharm, 92, 105-114.
21. Mehvar R. (1999). Simultaneous analysis of dextran-methylprednisolone succinate, methylprednisolone succinate, and methylprednisolone by size-exclusion chromatography. J Pharm Biomed Anal, 19, 785-792. (Pubitemid 29092781)
22. Mehvar R. (2000). Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J Control Rel, 69, 1-25.
23. Paiva LAF, Gurgel LA. (2004). Protective effect of Copaifera langsdorffii oleo-resin against acetic acid-induced colitis in rats. J Ethnopharmacol, 93, 51-56.
24. Pang YN, Zhang Y, Zhang ZR. (2002). Synthesis of an enzymedependent prodrug and evaluation of its potential for colon targeting. World J Gastroenterol, 8, 913-917.
25. Rodriguez M, Antunez JA, Taboada C, Seijo B, Torres D. (2001). Colon-specific delivery of budesonide from microencapsulated cellulosic cores: Evaluation of the efficacy against colonic inflammation in rats. J Pharm Pharmacol, 53, 1207-1215. (Pubitemid 32904015)
26. Sellin J. (2005). Treatment targets in inflammatory bowel disease. Adv Drug Del Rev, 57, 217-218. (Pubitemid 39536098)
27. Varshosaz J, Emami J, Tavakoli N, Fassihi A, Minaiyan M, Ahmadi F, Dorkoosh F. (2009). Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis. Int J Pharm, 365, 69-76.
28. Williams DA, Lemke TL. (2002). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins, Philadelphia, US.
29. Williams KL, Randall Fuller C, Dieleman LA, DaCosta CM, Haldeman KM, Balfour Sartor R, Kay Lund P. (2001). Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Gastroenterology, 120, 925-937.
30. Zou M, Okamoto H, Cheng G, Hao X, Sun J, Cui F., Danjo K. (2005). Synthesis and properties of polysaccharide prodrugs of 5- aminosalicylic acid as potential colon-specific delivery systems. Eur J Pharm Biopharm, 59, 155-160. (Pubitemid 39573448)